Amedisys, Inc. (NASDAQ:AMED) Given Consensus Rating of “Hold” by Brokerages

by · The Cerbat Gem

Amedisys, Inc. (NASDAQ:AMED – Get Free Report) has been assigned an average rating of “Hold” from the eight ratings firms that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $97.50.

A number of research analysts recently weighed in on AMED shares. Raymond James reaffirmed a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. StockNews.com assumed coverage on shares of Amedisys in a research report on Monday, April 8th. They issued a “buy” rating for the company. Finally, Royal Bank of Canada lifted their price objective on shares of Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 25th.

Read Our Latest Stock Analysis on AMED

Institutional Trading of Amedisys

Hedge funds have recently modified their holdings of the stock. KBC Group NV acquired a new stake in Amedisys in the 4th quarter worth about $41,000. Neo Ivy Capital Management acquired a new stake in Amedisys in the 2nd quarter worth about $44,000. Covestor Ltd raised its stake in Amedisys by 88.9% in the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock worth $56,000 after purchasing an additional 152 shares in the last quarter. Banque Cantonale Vaudoise acquired a new stake in Amedisys in the 1st quarter worth about $60,000. Finally, Acadian Asset Management LLC acquired a new stake in Amedisys in the 1st quarter worth about $67,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Down 0.4 %

Amedisys stock opened at $91.90 on Tuesday. The company has a market cap of $3.00 billion, a P/E ratio of -296.44, a price-to-earnings-growth ratio of 4.34 and a beta of 0.86. Amedisys has a 1-year low of $73.10 and a 1-year high of $96.44. The company has a fifty day simple moving average of $93.05 and a 200 day simple moving average of $93.49. The company has a current ratio of 1.05, a quick ratio of 1.05 and a debt-to-equity ratio of 0.32.

Amedisys (NASDAQ:AMED – Get Free Report) last released its earnings results on Wednesday, February 21st. The health services provider reported $0.94 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.10). The business had revenue of $570.79 million during the quarter, compared to the consensus estimate of $566.85 million. Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period last year, the business posted $1.16 EPS. Research analysts anticipate that Amedisys will post 4.54 earnings per share for the current fiscal year.

About Amedisys

(Get Free Report

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading